

---

---

**FORM 6-K**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For the Month of February, 2015

Commission File Number 1-32001

---

**Aptose Biosciences Inc.**

(Translation of registrant's name into English)

---

**2 Meridian Road, Toronto, Ontario M9W 4Z7**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_

---

---

**DOCUMENTS FILED AS PART OF THIS FORM 6-K**

See the Exhibit Index hereto.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Aptose Biosciences Inc.

Date: February 26, 2015

By: /s/ "Gregory Chow"

Gregory Chow

Senior Vice President and Chief Financial Officer

**EXHIBIT INDEX**

- 99.1 Press Release dated February 26, 2015 - Aptose Biosciences To Host Quarter and Seven Month Transition Period Ended December 31, 2014 Conference Call and Webcast

## **Aptose Biosciences To Host Quarter and Seven Month Transition Period Ended December 31, 2014 Conference Call and Webcast**

SAN DIEGO AND TORONTO, Feb. 26, 2015 /CNW/ - Aptose Biosciences Inc. (Aptose) (NASDAQ: APTO; TSX: APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced it intends to release financial results for the quarter and seven month transition period ended December 31, 2014, on Tuesday, March 3, 2015 after the close of the market. The company intends to host a conference call on the same day at 5:00 p.m. ET to discuss the financial results.

Participants can access the conference call by dialing 1-888-231-8191 (North American tollfree number) or 1-647-427-7450 (local). The conference call will be available via a live webcast at <http://www.newswire.ca/en/webcast/detail/1492275/1661947>, and will also available through a link on the Investor Relations section of Aptose's website at <http://www.apdose.com/events/>. Please log onto the webcast at least 10 minutes prior to the start of the call to ensure time for any software downloads that may be required. An archived version of the webcast will be available on the company's website for 30 days. An audio replay of the webcast will be available approximately two hours after the conclusion of the call for 30 days by dialing 1-855-859-2056, using the passcode 94751979.

The press release, the financial statements and the management's discussion and analysis for the quarter ended and seven month transition period ended December 31, 2014 will be available on SEDAR at [www.sedar.com](http://www.sedar.com) and EDGAR at [www.sec.gov/edgar.shtml](http://www.sec.gov/edgar.shtml)

### **About Aptose Biosciences**

Aptose Biosciences is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer research coupled with companion diagnostics to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed to provide additive or synergistic efficacy with existing anti-cancer therapies and regimens without overlapping toxicities. For further information, please visit [www.apdosebiosciences.com](http://www.apdosebiosciences.com).

### **Forward Looking Statements**

This press release contains forward-looking statements within the meaning of Canadian and U.S. securities laws. Such statements include, but are not limited to, statements relating to the Company's plans, objectives, expectations and intentions and other statements including words such as "continue", "expect", "intend", "will", "should", "would", "may", and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such expressed or implied forward looking statements could include, among others: our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

SOURCE Aptose Biosciences Inc.

PDF available at: [http://stream1.newswire.ca/media/2015/02/26/20150226\\_C9820\\_DOC\\_EN\\_43394.pdf](http://stream1.newswire.ca/media/2015/02/26/20150226_C9820_DOC_EN_43394.pdf)

%CIK: 0000882361

### **For further information:**

#### **Aptose Biosciences**

Greg Chow, CFO  
416-798-1200  
[gchow@aptose.com](mailto:gchow@aptose.com)

#### **BCC Partners**

Karen L. Bergman or Susan Pietropaolo  
650-575-1509 or 845-638-6290  
[kbergman@bccpartners.com](mailto:kbergman@bccpartners.com) or [spietropaolo@bccpartners.com](mailto:spietropaolo@bccpartners.com)

CO: Aptose Biosciences Inc.

CNW 08:00e 26-FEB-15